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Objective: The Lewy body dementias (LBD, dementia with Lewy bodies and Parkinson’s disease demen-
tia) are the second most common cause of neurodegenerative dementia but remain under-recognised,
with long delays from initial assessment to diagnosis. Whilst validated instruments have been developed
for key symptoms, there is no brief instrument for overall diagnostic assessment suitable for routine
practice. We here report the development of such assessment toolkits.
Methods: We developed the LBD assessment toolkits in three stages. First, we conducted a systematic
search for brief validated assessments for key symptoms and combined these into draft instruments.
Second, we obtained feedback on acceptability and feasibility through two rounds of interviews with
our patient and public involvement group. This led to modification of the toolkits. Finally, we piloted
the toolkits in a feasibility study in routine dementia and Parkinson’s disease services to produce final
instruments suitable for routine clinical practice.
Results: Eleven clinicians, working in both dementia/memory assessment and Parkinson’s
disease/movement disorder services, consented to pilot the assessment toolkits and provide feedback
on their feasibility. Clinicians worked in routine health service (not academic) settings and piloted
the draft toolkits by integrating them into their regular clinical assessments. Feedback obtained infor-
mally, by written comments and through qualitative interviews led to modifications and production
of final acceptable versions.
Conclusions: We were able to address an important need, the under-diagnosis of LBD, by developing
toolkits for improving the recognition and diagnosis of the LBD, which were acceptable to clinicians
working in routine dementia and Parkinson’s disease services.# 2016 The Authors. International Jour-
nal of Geriatric Psychiatry Published by John Wiley & Sons, Ltd.
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Introduction
The accurate recognition of dementia and the diagno-
sis of subtype of dementia ensure appropriate manage-
ment and are central to improving patient care for
those with dementia. Dementia with Lewy bodies
(DLB) is the second most common cause of degener-
ative dementia in older people after Alzheimer’s
disease (Stevens et al., 2002). Dementia also develops
in up to 80% of people with Parkinson’s disease,
(PDD) (Aarsland et al., 2003)]. Prevalence estimates
from both clinical and epidemiological samples of
Parkinson’s disease (PD) subjects indicate that at least
30% of those with PD have dementia (Riedel et al.,
2010), whilst longitudinal study shows that 80% of
those with PD will eventually develop dementia
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(Aarsland et al., 2003). PDD and DLB together are
known as Lewy body dementias (LBD) because they
share common clinical features, have closely overlap-
ping neurobiology and respond to similar management
approaches (Aarsland et al., 2004). Taken together,
LBD accounts for 10–15% all cases of dementia (Ste-
vens et al., 2002), affecting around 100,000 people in
the UK. Whilst both DLB and PDD share the problems
of under-recognition and inappropriate management,
the reason for these problems differs between DLB
and PDD.
Despite the known prevalence of DLB, it has been es-
timated that only around one in three cases are cur-
rently detected in routine care in the UK (Alzheimer
Society, 2007); for every DLB case properly diagnosed,
another two are either not detected or misdiagnosed,
usually as Alzheimer’s disease. Furthermore, the route
to diagnosis for patients with DLB is often protracted
with one US study reporting that half of the patients
had more than 10 clinic visits before the correct diag-
nosis was made(Galvin et al., 2010)]. There are several
reasons for these difficulties with recognition including
lack of assessment of key clinical symptoms such as hal-
lucinations, fluctuation and sleep disorder in dementia
assessment services and the challenges in eliciting mo-
tor features of parkinsonism in those with dementia
(Ballard et al., 1997).Changing practices in dementia
assessment services also mean that initial assessments
are often carried out by non-medical staff who are
not able to perform neurological examinations.
Improving the accuracy of detection and diagnosis of
PDD raises related but also distinct issues. Although pa-
tients with PD are often under regular follow-up in
neurology or geriatric medicine services only around
one in three of those with PDD are currently recognised
and diagnosed(Dujardin et al., 2010), and usually late in
their illness. Again, there are several reasons for missed
and delayed diagnosis of PDD: (1) cognitive impair-
ment develops insidiously and at a variable time after
PD diagnosis; (2) initial symptoms such as fluctuation,
attentional problems and hallucinations may be thought
to be related to medication side effects; (3) there is a
general lack of awareness of the benefits of diagnosing
dementia and a reluctance of professionals to disclose
the diagnosis; (4) cognition is often not routinely
assessed in neurology and geriatric medicine clinics. As
with DLB, the recognition of dementia in PD brings
the clear management benefits recognised for all those
with dementia, including allowing the prescription of
anti-dementia medication, provision of support, educa-
tion and advice, access to services, financial and other
benefits and opportunities for future planning and at-
tending to medico-legal issues(O’Brien et al., 2011).
Considerable progress has been made in developing
quick and validated tools for the assessment of key clin-
ical symptoms of LBD, e.g. the Lewy Body Composite
Risk Score (LBCRS) (Galvin, 2015). However, there is
no single, simple to administer toolkit which incorpo-
rates the range of clinical symptoms and which can be
used by clinicians broadly, e.g. the LBCRS assumes clin-
ical expertise not necessarily present in the staff carry-
ing out assessments in many clinics, and the LBCRS
does not directly link to the diagnostic criteria for
DLB. Hence, a brief assessment toolkit is needed, which
is suitable for use in routine practice by all clinical staff.
We report here the development of such toolkits as part
of a feasibility study to improve the recognition and di-
agnosis of both DLB and PDD as part of the National
Institute for Health Research (NIHR) ‘Improving the
diagnosis and management of neurodegenerative de-
mentia of Lewy body type’ study (DIAMOND Lewy
study).
Methods
We developed the LBD assessment toolkits in three
stages. First, we identified brief validated assessments
for different symptoms and signs that are key to making
an LBD diagnosis and then combined these into a pilot
instrument. Second, we obtained feedback on the
acceptability and feasibility of the toolkit through
interviews with patients, carers, clinicians and the pro-
gramme patient and public involvement (PPI) group.
This was used to modify the toolkits prior to piloting.
Finally, we piloted the toolkits in a feasibility study in
Dementia and PD services and modified the instrument
to a final acceptable version suitable for use in routine
clinical practice.
Development of pilot assessment tools
Clinical experts (AJT, JPT, IM, LA, DB and JOB)
reviewed the published literature and supplemented
this by their expert knowledge to identify available
validated assessments instruments (Ballard et al., 1997;
Mosimann et al., 2008; Boeve et al., 2011; Lee et al.,
2014). Following funding, the DIAMOND Lewy pro-
gramme management group (PMG) first discussed the
basic approach to the problem and, building on this ev-
idence, concluded two different instruments would be
needed, one for DLB and one for PDD. These would
be matched to the international diagnostic criteria for
DLB (McKeith et al., 2005) and PDD(Emre et al.,
2007). The PMG identified appropriate components
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for each toolkit from the identified assessment
instruments.
For the DLB toolkit, the aim was to improve
identification of the core and suggestive diagnostic
symptoms, because diagnosis of cognitive impairment
and dementia in specialist dementia services is not a
concern. There are six core and suggestive symptoms
for diagnosing DLB. One is dopaminergic imaging,
which would not form part of a clinical assessment tool,
and another is neuroleptic sensitivity which can only be
identified following exposure to antipsychotic drugs,
which is now a rare event (Walker et al., 2014). Hence,
the focus was on assessment of the four remaining
symptoms: persistent complex visual hallucinations,
spontaneous cognitive fluctuations, spontaneous par-
kinsonism and Rapid eye movement sleep behaviour
disorder (RBD). The following components of the in-
strument were identified:
a) Cognitive fluctuation. Four questions to carers from
the Dementia Cognitive Fluctuation Scale (Lee et al.,
2014).
b) Rapid eye movement. A single screening question to
carers from the Mayo Sleep Questionnaire (Boeve
et al., 2011).
c) Visual hallucinations. Two core questions for
patients and two for carers from the North East
Visual Hallucinations Inventory (Mosimann et al.,
2008).
d) Motor features of parkinsonism: five items from the
Unified Parkinson’s Disease Rating Scale (Ballard
et al., 1997).
For the PDD tool, the aim was to improve identifica-
tion of cognitive impairment and to facilitate matching
of symptoms to the PDD diagnostic criteria (Emre
et al., 2007). The Montreal cognitive assessment
(MoCA) was identified as most appropriate for brief
cognitive assessment in this context (Nasreddine et al.,
2005).
AT then put together the two instruments and after
iteration with the rest of the PMG, a draft version was
sent to the PPI panel. The PPI panel, including
patients and carers, then contributed comments, and
this feedback was incorporated into a revised version
which was again commented on by the PPI members
until a final agreed version and text was agreed for the
pilot study. These two iterative rounds led to changes
in wording of questions to try and improve clarity,
and the major change suggested was to separate the
PDD tool into one version for use with carers and one
for use with patients, based on how patients present
to PD services where they may or may not have a carer
present. After final iterations between PMG and PPI
groups, three final assessment toolkits were produced
for the pilot and feasibility study (Appendix 1)
Pilot and feasibility of assessment toolkits
A pilot and feasibility study of the assessment
instruments was carried out within Gateshead Health
NHSFT, a representative Trust which provides old age
psychiatry (memory/dementia) services (OAP) and
PD (movement disorder) services. Following ethical
and research and development approvals from Gates-
head Health NHSFT, medical and nursing staff were
identified in the OAP and PD services and given brief
information about the study and brief training in using
the assessment tools. The aims of the pilot was to en-
sure that the diagnosis tools were acceptable to staff
and could be integrated into current assessment proce-
dures in busy clinical services. Piloting was to include
all subjects having first assessments for memory impair-
ments and/or dementia because of possible Alzheimer’s
disease or other causes in the OAP service, and in the
PD Service, all those with PD where any cognitive im-
pairment was suspected. The aim was to include at least
four staff (doctors and nurses) in each service and at
least 20 subjects per service. Completed assessment
toolkits were kept by the research team with copies
placed in the patient notes.
Results
Four OAP consultants and four Elderly Medicine PD
clinicians (two specialist nurses and two consultants)
agreed to take part initially. Three additional clinicians
who were on leave or not initially working within the
service were subsequently recruited (two specialist
registrars within the OAP service and one consultant
from the PD Service) to increase opportunities for
accrual.
Patient recruitment
The number of patients consenting for the use of the
tool(s) by individual clinicians ranged from zero to
seven. Two PD clinicians did not use the assessment
tool (one clinician moved from the service soon after
the pilot study started, the other felt it was not appro-
priate for any of their patients) but a later PD clinician
did. All OAP clinicians used the assessment tool at least
once. Clinicians working in OAP recruited more pa-
tients (a total of 19) than their colleagues in the PD ser-
vice (a total of seven).
Assessment toolkits for Lewy body dementias
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The toolkits were used with patients with and with-
out LBD (Table 1). One patient had diagnoses of both
vascular dementia and PD, and therefore, the total
number of diagnoses was 27. Patients with PD may be
seen by the OAP service and the movement disorder
service, and during the study period, one patient was
seen by both services at different times and completed
the appropriate assessment tool in each service.
Feedback and modification of the assessment
toolkits
Feedback from clinicians was obtained in a number of
ways:
• Informal feedback to the local chief investigator
(AT) and the research nurse
• Writen comments on completed assessment tools
• Quaitative interviews (CB).
For the patients, none of the questions from the as-
sessment toolkits stood out as being inappropriate or
unclear. For clinicians generally, the tools were found
to be straightforward to use, with the constraints being
on time available within current service structures. The
PD service in particular found it difficult to integrate a
cognitive assessment into their initial patient assess-
ment. The toolkits were regarded as helpful in encour-
aging the assessment of the relevant symptoms for
diagnosis and useful in providing structure and a spe-
cific approach.
Based on detailed feedback in these ways, the pilot
toolkits were modified as follows (final DLB and PDD
assessment toolkits are in Appendices 2 and 3, respec-
tively). PD clinicians felt it would be helpful to have
questions on core and suggestive symptoms of DLB in
the PDD toolkit and did not feel that in practice, there
was a need to have separate carer and patient versions
of the PDD tool. Hence, the revised final version for
PD services (Appendix 3) is titled ‘Assessment toolkits
for Lewy body dementia’ and includes two toolkits, de-
pending on whether the patient has longstanding PD
and recent cognitive decline or whether the PD
diagnosis/symptoms are recent, along with cognitive
symptoms. A specific issue raised for RBD was what to
do if no bed-partner was available to answer the RBD
question. AT contacted Dr Brad Boeve (Mayo Clinic,
Minnesota) who had developed the RBD instrument
and was advised that a similar question can be used with
patients who are mildly cognitively impaired about any
known history of ‘acting out dreams’. This additional
option was therefore included in the final versions. In
the pilot version of the PD toolkits, the MoCA had been
specified. However, PD nurses were not familiar with the
MoCA, although they aimed to complete anMini-Mental
State Examination annually with each patient, and clini-
cians suggested that it be clarified that other cognitive in-
struments could be used if these were preferred, which
has been performed in the final LBD toolkit. A third spe-
cific concern was that the wording, whilst clear, some-
times appeared prescriptive and seemed to not allow
clinical judgement about the presence of symptoms,
and so the wording has been changed at several points
to make it clear that the questions in the toolkits are a
guide, and ultimately, the presence of key symptoms,
like final diagnoses, is a clinical judgement based on all
available evidence. Several other more minor issues were
raised about the layout and format which have been
incorporated into the final versions of the toolkits,
e.g. consistent use of tick boxes and an expanded list of
diagnostic options for people with cognitive impairment.
Thus, following the pilot feedback led to changes in
the assessment instruments. Specifically, a single PD as-
sessment toolkit was produced which included the
questions from the DLB toolkit for identifying visual
hallucinations, cognitive fluctuations and RBD. Word-
ing was also changed as was some of the layout in
response to comments.
Discussion
We were able to combine elements from validated
symptom assessment instruments into assessment
toolkits for improving the diagnosis of DLB and PDD.
These toolkits were developed to be aligned with the
standard diagnostic criteria for these dementias
(McKeith et al., 2005; Emre et al., 2007), and our
Table 1 Diagnoses of participating patients
Possible/probable
DLB
Non-DLB - other diagnoses including depression,
vascular dementia and mild cognitive impairment
PDD or
PD-MCI
Parkinson’s
disease
Use of tool(s) 5 12 2 8
Qualitative interview 3 2 0 1
DLB, dementia with Lewy bodies; PDD, Parkinson’s disease dementia; PD-MCI, Parkinson’s disease-mild cognitive impairment.
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feasibility study proved to be broadly acceptable to cli-
nicians in regular clinical services and easily integrated
into routine care making them ‘invisible’ to patients
during clinical assessments. The piloting of these
toolkits identified a few key changes, such as the desire
for a combined LBD toolkit for use with both patients
and carers in PD services, and the addition of an RBD
question for use when no bed-partner is available.
The study aimed to address the problem of inade-
quate recognition and diagnosis of both DLB (Galvin
et al., 2010; Alzheimer Society, 2007) and PDD
(Dujardin et al., 2010) and self-consciously sought to
build on existing evidence by utilising previously
researched and validated instruments (Ballard et al.,
1997; Mosimann et al., 2008; Boeve et al., 2011; Lee
et al., 2014). We did not therefore seek to assess the psy-
chometric properties of the specific elements of the
toolkits; rather we sought to address the need to com-
bine these instruments into clinically useful and usable
toolkits for clinicians working in dementia and PD ser-
vices. Following this feasibility study, the toolkits will re-
quire further testing in other clinical populations to
examine if they do indeed improve the diagnosis of
LBD. Although the absence of validation may be
regarded as a limitation, the fact the components have
been tested and validated previously provides some reas-
surance. The piloting of these toolkits in a single organi-
sation may also be regarded as a limitation of this study.
Finally whilst we had an adequate number of OAP clini-
cians using the toolkits, we only had three PD clinicians.
Whilst our study was deemed to have reached satura-
tion, we acknowledge that future assessments of these
toolkits will require more PD clinicians. However, the
aimwas to improve utility of the instruments in routine
dementia, and PD services and the clinicians involved
were not academics or researchers and are representa-
tive of clinicians in such services in the UK. Further-
more, it was clear from the feedback that we had
reached saturation, making it unlikely that involvement
of additional clinicians would have contributed usefully
to the study. Although the instruments were not them-
selves regarded as burdensome, the intense pressure on
clinicians’ time sometimes made it difficult for them
to use them, raising questions about how current service
designs might be hindering high quality diagnostic
assessments. One consequence of such pressures is that
nursing staff are often conducting parts of the clinical
assessments in many services and in order to assess
Parkinsonism they require specialist training.
In conclusion, we sought to address an important
need with this study, namely the under-recognition and
under-diagnosis of LBD in routine services. We have per-
formed this by developing brief and usable instruments
which can be integrated into routine clinical practice.
The pilot versions proved acceptable to clinicians and
patients, and we encourage the use of the final versions
to improve the diagnostic rates of DLB and PDD.
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